7 research outputs found
Response surface optimisation of vertical axis wind turbine at low wind speeds
The Vertical Axis Wind Turbines (VAWTs) have an increasing global market and this emphasis the need for to improve the performance of VAWTs, especially at relatively low wind speed. This paper utilises the Response Surface methodology to optimise the performance of a VAWT. A three bladed VAWT configuration was considered with a NACA0015 profile. Three significant input parameters were selected including the tip speed ratio, the turbine solidity, and the pitch angle. An extended range of each input parameter was chosen in order to gain a good insight into how these input parameters affect the performance of the VAWT. The high-fidelity Computational Fluid Dynamics (CFD) simulations were carried out for the modelling of the turbine. The use of the Response Surface Optimisation based on Multi-Objective Genetic Algorithm (MOGA) along with the CFD simulations is found to be useful in the selection of the optimal design of VAWT. Moreover, the 3D aspects of the VAWT geometry are investigated and these include the turbine aspect ratio and the effect of the blade tip geometry. The implementation of an optimised winglet at the tip of the turbine blades is found to provide a significant enhancement of the cycle averaged power coefficient, especially at low aspect ratios
SUPERPOSED DEFORMATION IN THE NORTHERN SUEZ RIFT, EGYPT: RELEVANCE TO HYDROCARBONS EXPLORATION
Design Method for Optical Waveguide Filters Having Corrugation Structures by Corrugation Width Modulation
Biomimetic complexes of Mn(II), Fe(III), Co(II), and Ni(II) with 1,10-phenanthroline and a salen type ligand: tailored synthesis, characterization, DFT, enzyme kinetics, and antibacterial screening
Antiinflammatory therapy with canakinumab for atherosclerotic disease
BACKGROUND: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. METHODS: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. RESULTS: At 48 months, the median reduction from baseline in the high-sensitivity C-reactive protein level was 26 percentage points greater in the group that received the 50-mg dose of canakinumab, 37 percentage points greater in the 150-mg group, and 41 percentage points greater in the 300-mg group than in the placebo group. Canakinumab did not reduce lipid levels from baseline. At a median follow-up of 3.7 years, the incidence rate for the primary end point was 4.50 events per 100 person-years in the placebo group, 4.11 events per 100 person-years in the 50-mg group, 3.86 events per 100 person-years in the 150-mg group, and 3.90 events per 100 person-years in the 300-mg group. The hazard ratios as compared with placebo were as follows: in the 50-mg group, 0.93 (95% confidence interval [CI], 0.80 to 1.07; P=0.30); in the 150-mg group, 0.85 (95% CI, 0.74 to 0.98; P=0.021); and in the 300-mg group, 0.86 (95% CI, 0.75 to 0.99; P=0.031). The 150-mg dose, but not the other doses, met the prespecified multiplicity-adjusted threshold for statistical significance for the primary end point and the secondary end point that additionally included hospitalization for unstable angina that led to urgent revascularization (hazard ratio vs. placebo, 0.83; 95% CI, 0.73 to 0.95; P=0.005). Canakinumab was associated with a higher incidence of fatal infection than was placebo. There was no significant difference in all-cause mortality (hazard ratio for all canakinumab doses vs. placebo, 0.94; 95% CI, 0.83 to 1.06; P=0.31). CONCLUSIONS: Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. Copyright © 2017 Massachusetts Medical Society